Gw Pharmaceuticals Plc (GWPH) Holder Scopia Capital Management LP Increased Its Position by $61.65 Million

April 16, 2018 - By Nellie Frank

Matt Sirovich increased its stake in Gw Pharmaceuticals Plc (GWPH) by 15.63% based on its latest 2017Q4 regulatory filing with the SEC. Scopia Capital Management Lp bought 467,035 shares as the company’s stock declined 18.69% with the market. The hedge fund run by Matt Sirovich held 3.46 million shares of the major pharmaceuticals company at the end of 2017Q4, valued at $456.10 million, up from 2.99M at the end of the previous reported quarter. Scopia Capital Management Lp who had been investing in Gw Pharmaceuticals Plc for a number of months, seems to be bullish on the $3.46 billion market cap company. The stock decreased 0.89% or $1.1 during the last trading session, reaching $122.85. About 83,025 shares traded. GW Pharmaceuticals plc (NASDAQ:GWPH) has declined 9.18% since April 16, 2017 and is downtrending. It has underperformed by 20.73% the S&P500.

Scopia Capital Management Lp, which manages about $7.11B and $5.57B US Long portfolio, decreased its stake in Jd Com Inc (NASDAQ:JD) by 1.38M shares to 5.00 million shares, valued at $207.11 million in 2017Q4, according to the filing. It also reduced its holding in Netflix Inc (NASDAQ:NFLX) by 309,780 shares in the quarter, leaving it with 2.04M shares, and cut its stake in Spirit Aerosystems Hldgs Inc (NYSE:SPR).

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Coverage

Among 5 analysts covering GW Pharma (NASDAQ:GWPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. GW Pharma had 9 analyst reports since October 26, 2017 according to SRatingsIntel. On Tuesday, February 6 the stock rating was maintained by Bank of America with “Buy”. The firm earned “Buy” rating on Monday, December 4 by Cantor Fitzgerald. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) earned “Buy” rating by Leerink Swann on Thursday, December 28. The stock of GW Pharmaceuticals plc (NASDAQ:GWPH) has “Outperform” rating given on Tuesday, February 6 by Leerink Swann. Bank of America maintained GW Pharmaceuticals plc (NASDAQ:GWPH) rating on Tuesday, November 14. Bank of America has “Buy” rating and $158 target. Goldman Sachs upgraded the shares of GWPH in report on Thursday, December 14 to “Buy” rating. The rating was maintained by Cantor Fitzgerald with “Buy” on Monday, February 5. Leerink Swann maintained the stock with “Buy” rating in Tuesday, January 23 report. The stock has “Buy” rating by Cowen & Co on Thursday, October 26.

GW Pharmaceuticals plc (NASDAQ:GWPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.